REGULATORY
Hemlibra, Lynparza, Zejula Face Quarterly Re-Pricing, 7.7-10.2% Cut in November
Three drugs including Chugai Pharmaceutical’s hemophilia A drug Hemlibra (emicizumab) were newly caught by quarterly price reviews, facing reductions of 7.7-10.2% under market expansion re-pricing, effective November 1. The two other drugs to be hit by the rule are AstraZeneca’s…
To read the full story
REGULATORY
- LDP Kampo Caucus Chief Wary of Removing Insurance Coverage
November 10, 2025
- LDP Panel Backs Support for Drug Wholesalers in Economic Package
November 10, 2025
- Downstream Providers Decry Growing Negative Margins at Ryukaikon
November 10, 2025
- Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
November 10, 2025
- MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…






